Advertisement

Cancer Immunology, Immunotherapy

, Volume 35, Issue 2, pp 97–105 | Cite as

Interleukin-6 and renal cell cancer: Production, regulation, and growth effects

  • Alec S. Koo
  • Cathy Armstrong
  • Bernard Bochner
  • Tomoyuki Shimabukuro
  • Cho-Lea Tso
  • Jean B. deKernion
  • Arie Belldegrun
Original articles

Summary

Interleukin-6 (IL-6) is a recently characterized pleiotropic cytokine with antitumor activity. We investigated the production of IL-6 by renal cell cancer (RCC) and the growth effects of IL-6 on RCC. Using immunoperoxidase staining, cytoplasmic IL-6 was detected in four of four renal tumor lines and in tumor cells from freshly nephrectomized RCC. We found that IL-6 mRNA was expressed at basal culture conditions by seven of ten RCC tumor lines tested. Biologically active IL-6, as measured by the B9 assay, was produced by all ten RCC tumor lines. The addition of tumor necrosis factor α (TNFα) significantly augmented the expression of IL-6 mRNA in five RCC tumor lines (P <0.05). The combination of interferon γ IFNγ and TNFα further enhanced the augmented IL-6 mRNA accumulation seen with TNFα alone (P <0.05). TNFα also significantly stimulated the production of biologically active IL-6 (P <0.01). Furthermore, IFNγ and TNFα were found to enhance IL-6 bioactivity synergistically (P <0.05). The growth effects of IL-6 on RCC were also investigated in two experimental systems: IL-6 was found to stimulate proliferative responses in six of six RCC tumor lines as measured by thymidine-uptake assays; however, only one of six tumor lines displayed an increase in proliferative response of greater than 21% (113%). The growth effect of IL-6 was further tested in clonogenic assays. One of the tumor lines tested displayed an enhanced growth response of up to 200%. We conclude that IL-6 is produced by RCC; this production is enhanced by TNFα with synergistic effects seen with IFNγ at both mRNA and protein levels. In turn, IL-6 may have a modest stimulatory growth effect on certain RCC tumor lines.

Key words

Interleukin-6 Renal cell cancer Growth effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aarden L, Lansdorp P, DeGroot E (1985) A growth factor for B cell hybridomas produced by human monocytes. Lymphokines 10: 175Google Scholar
  2. 2.
    Aarden LA, DeGroot ER, Schaap OL, Lansdorf P (1987) Production of hybridoma growth factor by human monocytes. Eur J Immunol 17: 1411Google Scholar
  3. 3.
    Akashi M, Loussararian AH, Adelman DC, Saito M, Koeffler HP (1990) Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. J Clin Invest 85: 121Google Scholar
  4. 4.
    Betsholtz C, Westermark B, Ek B, Heldin CH (1984) Co-expression of a PDGF like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activity. Cell 39: 447Google Scholar
  5. 5.
    Brach BA, Cicco NA, Riedel D, Hirano T, Kishimoto T, Mertelsmann RH, Herrmann F (1990) Mechanisms of differential regulation of interleukin-6 mRNA accumulation by tumor necrosis factor α and lymphotoxin during monocytic differentiation. FEBS Lett 263: 349Google Scholar
  6. 6.
    Brouckaert PGG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W (1986) In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFNγ, on a syngeneic murine melanoma. Int J Cancer 38: 763Google Scholar
  7. 7.
    Brouckaert P, Spriggs D, Demetri G, Kufe DW, Fiers W (1989) Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon γ. J Exp Med 169: 2257Google Scholar
  8. 8.
    Chen L, Mory Y, Zilberstein A, Revel M (1988) Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-B2. Proc Natl Acad Sci USA 85: 8037Google Scholar
  9. 9.
    Content J, De Wit L, Poupart P, Opdenakker G, Van Damme J, Billiau A (1985) Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor. Eur J Biochem 152: 253Google Scholar
  10. 10.
    Damme JV, Opdenakker G, Simpson RJ, Rubira MR, Cayphas S, Vink A, Billau A, Snick JV (1987) Identification of the human 26-kD protein, interferon B2(IFN-B2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 165: 914Google Scholar
  11. 11.
    Defilippi P, Poupart P, Tavernier J, Fiers W, Content J (1987) Induction and regulation of mRNA encoding 26-kDa protein in human cell lines treated with recombinant human tumor necrosis factor. Proc Natl Acad Sci USA 84: 4557Google Scholar
  12. 12.
    Demetri GD, Spriggs DR, Sherman ML, Arthur K, Imamura K, Frei III E, Kufe DW (1988) Recombinant human tumor necrosis factor and gamma interferon: phase I study of therapy with overlapping 24 hour infusions. Proc Am Soc Clin Oncol Annu Meet 7: 173Google Scholar
  13. 13.
    Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figarl IS, Falladino MA, O'Connor JB (1986) Tumor necrosis factor(cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163: 1433Google Scholar
  14. 14.
    Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H (1987) Interferon b2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84: 7251Google Scholar
  15. 15.
    Gomella LG, Sargent ER, Wade TR, Anglard P, Linehan WM, Kasid A (1989) Expression of transforming growth factor α in normal human adult kidney and enhanced expression of transforming growth factors α and β1 in renal cell carcinoma. Cancer Res 49: 6972Google Scholar
  16. 16.
    Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461Google Scholar
  17. 17.
    Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi Y, Kishimoto T (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73Google Scholar
  18. 18.
    Horii Y, Maraguchi A, Suematsu S, Matsuda T, Yoshizaki K, Hirano T, Kishimoto T (1988) Regulation of BSF-2/IL-6 production by human mononuclear cells. J Immunol 141: 1529Google Scholar
  19. 19.
    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83Google Scholar
  20. 20.
    Kishimoto T (1987) B cell stimulatory factors(BSFs). Molecular structure, biological function, and regulation of expression. J Clin Immunol 7: 343Google Scholar
  21. 21.
    Kohase M, Henriksen-DeStefano D, May LT, Vilcek J, Sehgal PB (1986) Induction of B2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell 45: 659Google Scholar
  22. 22.
    Kohase M, May LT, Tamm I, Vilcek J, Sehgal PB (1987) A cytokine network in human diploid fibroblasts: interaction of B-interferons, tumor necrosis factor, platelet-derived growth factor, and interleukin-1. Mol Cell Biol 7: 273Google Scholar
  23. 23.
    Leary AG, Ikebuchi K, Hirai Y, Wong GG, Yang YC, Clark SC, Ogawa M (1988) Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoetic stem cells; comparison with interleukin-1α. Blood 71: 1759Google Scholar
  24. 24.
    Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ, Shepard HM (1987) Modulation of the growth of transformed cells by human tumor necrosis factor-α and interferon-γ. Cancer Res 47: 5382Google Scholar
  25. 25.
    Lowik CWGM, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OLM, Aarden LA, Papapoulos SE (1989) Parathyroid hormone (PTH) and PTH-like protein (PLP) production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 162: 1546Google Scholar
  26. 26.
    May LT, Helfgott DC, Sehgal PB (1986) Anti-B-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the B2 interferon involved. Proc Natl Acad Sci USA 83: 8957Google Scholar
  27. 27.
    Miki S, Iwano M, Miki Y, Yamamato M, Tang B, Yokokawa K, Sonoda T, Dirano T, Kishimoto T (1989) Interleukin 6(IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250: 607Google Scholar
  28. 28.
    Miles SA, Rezai AR, Salazar-Gonzalez JF, Meyden MV, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, Martinez-Maza O (1990) AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87: 4068Google Scholar
  29. 29.
    Miyaura C, Onozaki K, Akiyama Y, Taniyama T, Hirano T, Kishimoto T, Suda T (1988) Recombinant human interleukin 6(B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1). FEBS Lett 234: 17Google Scholar
  30. 30.
    Mule JJ, McIntosh JK, Jablons DM, Rosenberg SA (1990) Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 171: 629Google Scholar
  31. 31.
    Nijstein MWN, DeGroot ER, Ten Duis JH, Hack CE, Aarden LA (1987) Serum levels of interleukin-6 and acute phase responses. Lancet 2: 921Google Scholar
  32. 32.
    Ramakrishran S, Xu FJ, Brant SJ, Niedel JE, Bast RD Jr, Brown EL (1989) Constitutive production of macrophage colony-stimulating factor by human ovarian and breast carcinoma cell lines. J Clin Invest 83: 921Google Scholar
  33. 33.
    Schwab G, Siegall C, Aarden L, Neckers L, Nordan R (1990) Identification of an IL-6-modulated autocrine growth loop in a human multiple myeloma cell line. Proc Am Assoc Cancer Res 31: 243Google Scholar
  34. 34.
    Tosato G, Gerrard TL, Goldman NG, Pike SE (1988) Stimulation of EBV-activated human B cells by monocytes and monocyte products. J Immunol 140: 4329Google Scholar
  35. 35.
    Tosato G, Tanner J, Jones KD, Revel M, Pike SE (1990) Identification of Interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 64: 3033Google Scholar
  36. 36.
    Tweeddale M, Jamal N, Nguyen A, Wang XH, Minden MD, Messner HA (1989) Production of growth factors by malignant lymphoma cell lines. Blood 74: 572Google Scholar
  37. 37.
    Van Damme J, Van Beeumen H, Decock B, Van Snick J, De Ley M, Billiqu A (1988) Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1B and hybridoma growth factor(HGF). J Immunol 140: 1534Google Scholar
  38. 38.
    Watson JM, Sensintaffar J, Berek J, Martinez-Maza O (1990) Constitutive production of IL-6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50: 6959Google Scholar
  39. 39.
    Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clar SC, Messner HA, Minden MD (1989) A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74: 798Google Scholar
  40. 40.
    Zilberstein A, Ruggieri R, Korn JH, Chen L, Mory Y, Shulman L, Revel M (1987) Biological activities of human interferon B-2 produced by cDNA expression in hamster cells and possible autocrine functions of this cytokine-induced IFN. In: Cantell K, Schellekens H (eds) The biology of the interferon System. Nijhoff, Boston, p 165Google Scholar
  41. 41.
    Zilberstein A, Ruggieri R, Korn JH, Revel M (1989) Structure and expression of cDNA and genes for human interferon-β-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 5: 2529Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Alec S. Koo
    • 1
  • Cathy Armstrong
    • 1
  • Bernard Bochner
    • 1
  • Tomoyuki Shimabukuro
    • 1
  • Cho-Lea Tso
    • 1
  • Jean B. deKernion
    • 1
  • Arie Belldegrun
    • 1
  1. 1.Immunotherapy Laboratory, Division of Urology, Department of Surgery, and the Jonsson Comprehensive Cancer CenterUCLA School of MedicineLos AngelesUSA

Personalised recommendations